Majority of these therapeutic strategies are aimed at controlling symptomatic CF-lung disease, while some of the newer strategies are designed to target the primary or “root” cause of the disease, which is the mutation(s) in the cystic fibrosis transmembrane conductance regulator (Cftr) gene (Esposito et al., 2016; Hudock and Clancy, 2017; Maiuri et al., 2017; Zhang et al., 2018). This evidence concerns the gene CFTR and lung disorder.